Show simple item record

dc.contributor.authorO'Reilly, Aen_US
dc.contributor.authorLarkin, Jen_US
dc.coverage.spatialEnglanden_US
dc.date.accessioned2018-02-16T11:42:11Z
dc.date.issued2017-08en_US
dc.identifierhttps://www.ncbi.nlm.nih.gov/pubmed/28679287en_US
dc.identifier.citationExpert Opin Drug Saf, 2017, 16 (8), pp. 955 - 961en_US
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/1202
dc.identifier.eissn1744-764Xen_US
dc.identifier.doi10.1080/14740338.2017.1351537en_US
dc.description.abstractINTRODUCTION: Nivolumab, a human IgG4 monoclonal antibody directed against PD-1, is a checkpoint inhibitor that is licenced in the treatment of metastatic melanoma either as a monotherapy or in combination with ipilimumab, a CTLA-4 inhibitor. The introduction of immune checkpoint inhibitors to the therapeutic landscape has dramatically altered outcomes in a proportion of patients with metastatic melanoma. Immune checkpoint inhibitors result in a toxicity profile that is distinct from that of chemotherapy or targeted therapy based on their immunomodulatory mechanism and similarly can result in patterns of response that are unique. Areas covered: Herein we will profile nivolumab's efficacy and safety both as a combination therapy and a monotherapy and discuss the results of relevant clinical trials in this respect. Expert opinion: The future of immunotherapy in melanoma will evolve around the development of biomarkers, the refinement of criteria to define patterns of response and toxicity and the combination of current immunotherapies with existing and novel agents to maximise responses.en_US
dc.format.extent955 - 961en_US
dc.languageengen_US
dc.language.isoengen_US
dc.subjectMelanomaen_US
dc.subjectPD-1en_US
dc.subjectimmune related adverse eventsen_US
dc.subjectipilimumaben_US
dc.subjectnivolumaben_US
dc.subjectAntibodies, Monoclonalen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectCTLA-4 Antigenen_US
dc.subjectHumansen_US
dc.subjectImmunotherapyen_US
dc.subjectIpilimumaben_US
dc.subjectMelanomaen_US
dc.subjectNeoplasm Metastasisen_US
dc.subjectNivolumaben_US
dc.subjectProgrammed Cell Death 1 Receptoren_US
dc.titleThe safety of nivolumab for the treatment of metastatic melanoma.en_US
dc.typeJournal Article
rioxxterms.versionofrecord10.1080/14740338.2017.1351537en_US
rioxxterms.licenseref.startdate2017-08en_US
rioxxterms.typeJournal Article/Reviewen_US
dc.relation.isPartOfExpert Opin Drug Safen_US
pubs.issue8en_US
pubs.notesNot knownen_US
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Clinical Studies/Melanoma and Kidney Cancer/Melanoma and Kidney Cancer (hon.)
pubs.organisational-group/ICR/Primary Group/Royal Marsden Clinical Units
pubs.publication-statusPublisheden_US
pubs.volume16en_US
pubs.embargo.termsNot knownen_US
icr.researchteamMelanoma and Kidney Canceren_US
dc.contributor.icrauthorLarkin, Jamesen_US
dc.contributor.icrauthorMarsden,en_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record